CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, CML CD34+ cells display greater sensitivity to BMP pathway inhibition than normal CD34+ cells, undergoing fewer cell divisions, with reduced CD34+ cells numbers and colony formation occurring following treatment.